Molecular Partners AG

SWX:MOLN Voorraadrapport

Marktkapitalisatie: CHF 186.5m

Molecular Partners Beheer

Beheer criteriumcontroles 2/4

De CEO Molecular Partners is Patrick Amstutz, benoemd in Jan2004, heeft een ambtstermijn van 20.83 jaar. De totale jaarlijkse vergoeding van { bedraagt CHF 1.05M, bestaande uit 36.8% salaris en 63.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2% van de aandelen van het bedrijf, ter waarde CHF 3.72M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 4.6 jaar.

Belangrijke informatie

Patrick Amstutz

Algemeen directeur

CHF 1.0m

Totale compensatie

Percentage CEO-salaris36.8%
Dienstverband CEO20.8yrs
Eigendom CEO2.0%
Management gemiddelde ambtstermijn3.3yrs
Gemiddelde ambtstermijn bestuur4.6yrs

Recente managementupdates

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Apr 11
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Recent updates

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Sep 10
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Apr 11
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Jan 09
Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Sep 08
Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Jun 23
Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Aug 31
What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

May 09
Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Dec 26
Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Jun 24
We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Mar 09
Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts

Feb 10
Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Jan 21
Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?

Dec 17
How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?

Downgrade: Here's How Analysts See Molecular Partners AG (VTX:MOLN) Performing In The Near Term

Nov 21
Downgrade: Here's How Analysts See Molecular Partners AG (VTX:MOLN) Performing In The Near Term

Analyse CEO-vergoeding

Hoe is Patrick Amstutz's beloning veranderd ten opzichte van Molecular Partners's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-CHF 63m

Jun 30 2024n/an/a

-CHF 58m

Mar 31 2024n/an/a

-CHF 59m

Dec 31 2023CHF 1mCHF 385k

-CHF 62m

Sep 30 2023n/an/a

-CHF 60m

Jun 30 2023n/an/a

-CHF 62m

Mar 31 2023n/an/a

-CHF 50m

Dec 31 2022CHF 1mCHF 383k

CHF 118m

Sep 30 2022n/an/a

CHF 117m

Jun 30 2022n/an/a

CHF 118m

Mar 31 2022n/an/a

CHF 106m

Dec 31 2021CHF 1mCHF 380k

-CHF 64m

Sep 30 2021n/an/a

-CHF 67m

Jun 30 2021n/an/a

-CHF 72m

Mar 31 2021n/an/a

-CHF 66m

Dec 31 2020CHF 1mCHF 380k

-CHF 63m

Sep 30 2020n/an/a

-CHF 53m

Jun 30 2020n/an/a

-CHF 48m

Mar 31 2020n/an/a

-CHF 43m

Dec 31 2019CHF 930kCHF 363k

-CHF 36m

Sep 30 2019n/an/a

-CHF 37m

Jun 30 2019n/an/a

-CHF 38m

Mar 31 2019n/an/a

-CHF 38m

Dec 31 2018CHF 909kCHF 346k

-CHF 37m

Sep 30 2018n/an/a

-CHF 27m

Jun 30 2018n/an/a

-CHF 18m

Mar 31 2018n/an/a

-CHF 24m

Dec 31 2017CHF 885kCHF 344k

-CHF 25m

Compensatie versus markt: De totale vergoeding ($USD 1.22M ) Patrick } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 854.26K ).

Compensatie versus inkomsten: De vergoeding van Patrick is gestegen terwijl het bedrijf verliesgevend is.


CEO

Patrick Amstutz (49 yo)

20.8yrs

Tenure

CHF 1,047,000

Compensatie

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Patrick Amstutz
Co-Founder20.8yrsCHF 1.05m2%
CHF 3.7m
Michael Stumpp
Co-Founder20.8yrsgeen gegevens2.08%
CHF 3.9m
Robert Hendriks
Senior VP of Finance5.3yrsgeen gegevensgeen gegevens
Alexander Zurcher
COO & Member of Management Board2.3yrsgeen gegevens0.070%
CHF 130.2k
Renate Gloggner
Executive VP of People & Community and Member of Management Board2.9yrsgeen gegevens0.062%
CHF 116.5k
Daniel Steiner
Senior Vice President of Research & Technology3.7yrsgeen gegevensgeen gegevens
Seth Lewis
Senior Vice President of Investor Relationsno datageen gegevensgeen gegevens
Michael Pitzner
General Counsel2yrsgeen gegevensgeen gegevens
Pamela Trail
Strategic Consultant5.3yrsgeen gegevensgeen gegevens
Anne Goubier
Senior Vice President of Research & Early Development2.8yrsgeen gegevensgeen gegevens
Philippe Legenne
Chief Medical Officer1.3yrsgeen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MOLN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Patrick Amstutz
Co-Founder7.1yrsCHF 1.05m2%
CHF 3.7m
Steven H. Holtzman
Independent Non Executive Director10.5yrsCHF 135.00k0.040%
CHF 74.5k
William A. Burns
Independent Chairman of the Board7.1yrsCHF 295.00k0.073%
CHF 136.5k
Vito Palombella
Independent Director4.6yrsCHF 125.00k0.0095%
CHF 17.7k
Agnete Fredriksen
Independent Director3.6yrsCHF 125.00kgeen gegevens
Michael Vasconcelles
Independent Director4.6yrsCHF 135.00k0.0095%
CHF 17.8k
Sandip Kapadia
Independent Director4.6yrsCHF 130.00k0.0095%
CHF 17.8k
Dominik Hochli
Independent Director3.6yrsCHF 133.00kgeen gegevens

4.6yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MOLN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).